Edwards Lifesciences Corp (EW)vsPenumbra Inc (PEN)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
PEN
Penumbra Inc
$336.27
+0.63%
HEALTHCARE · Cap: $13.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 332% more annual revenue ($6.07B vs $1.40B). EW leads profitability with a 17.7% profit margin vs 12.7%. PEN appears more attractively valued with a PEG of 0.76. PEN earns a higher WallStSmart Score of 64/100 (C+).
EW
Buy55
out of 100
Grade: C
PEN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Margin of Safety
-60.3%
Fair Value
$211.07
Current Price
$336.27
$125.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Revenue surging 22.1% year-over-year
Earnings expanding 38.3% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Trading at 9.2x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : PEN
The strongest argument for PEN centers on Altman Z-Score, PEG Ratio, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : PEN
The primary concerns for PEN are Price/Book, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Key Dynamics to Monitor
EW profiles as a mature stock while PEN is a growth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
PEN is growing revenue faster at 22.1% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
PEN scores higher overall (64/100 vs 55/100) and 22.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Penumbra Inc
HEALTHCARE · MEDICAL DEVICES · USA
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?